uniQure N.V. (QURE) vs Stoke Therapeutics, Inc. (STOK)
- uniQure N.V. QURE 21.72 −3.55%
- Stoke Therapeutics, Inc. STOK 24.17 −1.79%
uniQure N.V. and Stoke Therapeutics, Inc. are both Biotechnology companies. uniQure N.V. and Stoke Therapeutics, Inc. are of similar size ($1.6B and $1.6B). uniQure N.V. grew revenue faster over the last twelve months: 30.2% against −86.2%. Stoke Therapeutics, Inc. has the higher net margin (−753.6% vs −1,350.7%) and the lower return on invested capital (−264.8% vs 0.00%). Across the 17 metrics below, Stoke Therapeutics, Inc. leads on 10 and uniQure N.V. on 7.
Valuation
Profitability
| Metric | QURE | STOK | Biotechnology median |
|---|---|---|---|
| Gross margin | 92.49% | 100.00% | 65.16% |
| Operating margin | (1,071.53%) | (809.69%) | 0.00% |
| Net margin | (1,350.73%) | (753.60%) | 0.00% |
| Free cash flow margin | (864.67%) | (654.92%) | 0.00% |
| Return on equity | (157.61%) | (61.10%) | (56.36%) |
| Return on assets | (32.13%) | (53.41%) | (48.04%) |
| Return on invested capital | 0.00% | (264.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack